Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetics, pharmacodynamics, and metabolism of triethylenetetramine in healthy human participants: an open-label trial.

Journal of clinical pharmacology - 1 Jun 2010

Lu Jun, Poppitt Sally D, Othman Asma A, Sunderland Tracey, Ruggiero Katya, Willett Michael S, Diamond Lisa E, Garcia Wilfredo D, Roesch Benno G, Cooper Garth J S

Abstract excerpt

The selective Cu(II)-chelator, triethylenetetramine (TETA), is undergoing clinical trials for the treatment of heart failure in patients with diabetes. Recently, the authors showed that 2 acetylated metabolites, N(1)-acetyltriethylenetetramine (MAT) and N(1),N(10)-diacetyltriethylenetetramine (DA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arylamine N-Acetyltransferase
Share to Chelating Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Copper

Share to NAT2 gene

Share to Phenotype

Share to Time Factors

Source

Identifiers

PMID: 20145262
DOI: 10.1177/0091270009349379

Genes

NAT2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20145262-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetics, pharmacodynamics, and metabolism of triethylenetetramine in healthy human participants: an open-label trial.PMID 20145262Read ↗

Unified pharmacogenetics-based parent-metabolite pharmacokinetic model incorporating acetylation polymorphism for talampanel in humans.Semantic proximity Read ↗

Efficacy and Safety of Two Salts of Trientine in the Treatment of Wilson DiseaseSemantic proximity Read ↗

Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study.Semantic proximity Read ↗

Case Study 10: A Case to Investigate Acetyl Transferase Kinetics.Semantic proximity Read ↗

Single-dose tolerability, pharmacokinetics, and pharmacodynamics of etamicastat (BIA 5-453), a new dopamine β-hydroxylase inhibitor, in healthy subjects.Semantic proximity Read ↗

Etamicastat, a novel dopamine β-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension.Semantic proximity Read ↗

Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) of peripheral blood.Semantic proximity Read ↗

Influence of the N-acetylation polymorphism on the metabolism of talampanel: an investigation in fasted and fed subjects genotyped for NAT2 variants.Semantic proximity Read ↗

Mesalazine pharmacokinetics and NAT2 phenotype.Semantic proximity Read ↗

T-type amino acid transporter TAT1 (Slc16a10) is essential for extracellular aromatic amino acid homeostasis control.Semantic proximity Read ↗

Acecainide pharmacokinetics in normal subjects of known acetylator phenotype.Semantic proximity Read ↗

Validity of an ELISA for N-acetyltransferase-2 (NAT2) phenotyping.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.